Pancreatic cancer cells treated with GSI showed a significant reduction in CSCs with the ESA+/CD44+/CD24+ marker profile compared to untreated cells (2.76±0.16% control vs. 1.43±0.15% with GSI p = 0.013) (Figure 2C,D). Here, CD44 is linked to pancreatic neoplasm.